Bj. Aungst et al., PRODRUGS TO IMPROVE THE ORAL BIOAVAILABILITY OF A DIACIDIC NONPEPTIDEANGIOTENSIN-II ANTAGONIST, Pharmaceutical research, 12(5), 1995, pp. 763-767
DMP 811 is a diacidic angiotensin II antagonist. It has relatively low
oral bioavailability in rats. A prodrug approach to improving oral bi
oavailability was tested. Five esters were synthesized and their stabi
lity in rat plasma in vitro was determined. The hydrolysis rates of th
ese five esters ranged from almost immediate to negligible. A simple n
-propyl ester was hydrolyzed very slowly (<10% in 24 hr) in rat plasma
in vitro, and after oral dosing in rats plasma prodrug concentrations
were much greater than DMP 811 concentrations. A pivaloyloxymethyl es
ter (1) was hydrolyzed relatively rapidly in rat plasma in vitro. Prod
rug 1 was rapidly hydrolyzed by the intestine in vitro, and the intest
inal permeation of DMP 811 was increased. DMP 811 oral bioavailability
was 47% in rats dosed with 10 mg/kg 1, compared to 11% for rats dosed
with 10 mg/kg DMP 811. However, DMP 811 bioavailability was only 27%
after a 2 mg/kg dose of 1. In vitro plasma hydrolysis of 1 was highly
species-dependent, with a half-life of 13 hr in human plasma but only
1 min in rat plasma. The prodrug approach has potential for improving
the oral bioavailability of DMP 811, but selection of the optimal prod
rug must be done in humans or in a species, such as dogs, with hydroly
sis characteristics closer to humans.